- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02745522
Can Oxytocin Enhance the Placebo Effect?
October 10, 2018 updated by: Keith Kendrick, University of Electronic Science and Technology of China
The current study aimed to investigate whether oxytocin (OXT) had effect on placebo effect.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The current study included three phases to investigate oxytocin effect on placebo effect:
- In a double-blind, between-subject, placebo controlled design study to investigate the intranasal OXT (24IU) treatment in 66 healthy male subjects using working memory task.
- In a single-blind(subjects were informed that the treatment was oxytocin), between-subject, placebo controlled design study to investigate the intranasal OXT (24IU) treatment in 53 healthy male subjects using working memory task.They were informed that oxytocin would increase memory perfomance by a female experimenter.
- In a single-blind(subjects were informed that the treatment was oxytocin), between-subject, placebo controlled design study to investigate the intranasal OXT (24IU) treatment in 53 healthy male subjects using working memory task. But the subjects were told that oxytocin would decrease the performance by the same female experimenter.
- In a single-blind(subjects were informed that the treatment was oxytocin), between-subject, placebo controlled design study to investigate the intranasal OXT (24IU) treatment in 52 healthy male subjects using working memory task. The subjects were told that oxytocin would increase the performance by a male experimenter.
Memory performance was included as dependant factor. All subjects completed a range of questionnaires measuring personality and affective traits and levels of anxiety: State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), Interpersonal Trust Scale(ITS).
Study Type
Interventional
Enrollment (Actual)
224
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 611731
- School of Life Science and Technology, University of Electronic Science and Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 30 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy subjects without past or current psychiatric or neurological disorder
Exclusion Criteria:
- history of head injury;
- claustrophobia;
- medical or psychiatric illness.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo nasal spray
|
|
Experimental: Oxytocin
Oxytocin nasal spray
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Memory performance in different phases
Time Frame: 1 hour
|
N-back memory performance (accuracy) was included into analysis.
|
1 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2015
Primary Completion (Actual)
March 1, 2017
Study Completion (Actual)
August 1, 2017
Study Registration Dates
First Submitted
March 11, 2016
First Submitted That Met QC Criteria
April 19, 2016
First Posted (Estimate)
April 20, 2016
Study Record Updates
Last Update Posted (Actual)
October 15, 2018
Last Update Submitted That Met QC Criteria
October 10, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UESTC-neuSCAN-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oxytocin Effect on Memory Performance During Phase 1
-
University of North Carolina, Chapel HillCompletedEffect of Fatty Acids on Memory Performance of ToddlersUnited States
-
Donders Centre for Cognitive NeuroimagingDr. Hanneke den Ouden, Donders Centre for Cognition, Radboud University; Dr... and other collaboratorsCompletedSulpiride's Effect on Striatal BOLD Signal During Working Memory Gating | Interaction of Sulpiride, Average Reward Rate and Evidence Accumulation | Interaction of Sulpiride, Average Reward Rate and Cognitive EffortNetherlands
-
PepsiCo Global R&DUnknownChange in Cognitive Function and Fatigue During Extended Performance of the Cognitive Demand Battery (CDB) at 1, 3 and 6 Hours Post Consumption | Change in Long Term Declarative Memory at 1, 3 and 6 Hours Post-intervention.United Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States